Results 91 to 100 of about 125,339 (239)

What doesn't kill you makes you stranger: Dipeptidyl peptidase-4 (CD26) proteolysis differentially modulates the activity of many peptide hormones and cytokines generating novel cryptic bioactive ligands [PDF]

, 2019
Dipeptidyl peptidase 4 (DPP4) is an exopeptidase found either on cell surfaces where it is highly regulated in terms of its expression and surface availability (CD26) or in a free/circulating soluble constitutively available and intrinsically active form.
Aguilar-Pérez, Alexandra, Awad, Mohamed E., Eisa, Nada H., Elmansi, Ahmed M., Fulzele, Sadanand, Hamrick, Mark W., Herberg, Samuel, Hill, William D., Hussein, Khaled A., Isales, Carlos M., Kondrikov, Dmitry, McGee-Lawrence, Meghan E., Periyasamy-Thandavan, Sudharsan, Volkman, Brian F.   +13 more
core   +1 more source

GLP‐1 Agonists for Pediatric Psychopharmacology: Opportunities and Cautions

Clinical and Translational Science
Glucagon‐like peptide‐1 agonists (GLP‐1A) are increasingly prescribed to treat obesity and type 2 diabetes mellitus in children and adolescents.
Michael Bartkoski, Ethan A. Poweleit, Stephani L. Stancil   +2 more
doaj   +1 more source

Glucagon receptor antagonist upregulates circulating GLP-1 level by promoting intestinal L-cell proliferation and GLP-1 production in type 2 diabetes

BMJ Open Diabetes Research & Care, 2020
ObjectiveGlucagon receptor (GCGR) blockage improves glycemic control and increases circulating glucagon-like peptide-1 (GLP-1) level in diabetic animals and humans.
Shan Lang, Liangbiao Gu, Xiaona Cui, Tianjiao Wei, Junling Liu, Yunyi Le, Rui Wei, Tianpei Hong   +7 more
doaj   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Genetic influences on the insulin response of the beta cell to different secretagogues [PDF]

, 2009
Aims/hypothesis: The aim of the present study was to estimate the heritability of the beta cell insulin response to glucose and to glucose combined with glucagon-like peptide-1 (GLP-1) or with GLP-1 plus arginine.
A Fritsche, A Haupt, A. M. C. Simonis-Bik, AM Simonis-Bik, B Ahren, B Newman, D Posthuma, D. I. Boomsma, DI Boomsma, E. J. C. de Geus, E. M. W. Eekhoff, F Medici, GW Mills, H Beck-Nielsen, HH Maes, I Prokopenko, J Kaprio, J. A. Maassen, J. M. Dekker, JB Meigs, JC Florez, JE Gerich, JF Gautier, JR Astles, L. M. ’t Hart, M Brandle, M Lehtovirta, M Lehtovirta, M Stumvoll, M. Diamant, M. H. H. Kramer, M. H. M. de Moor, MB Snijder, MC Neale, MC Neale, MI McCarthy, MJ Groenewoud, P Poulsen, R Huxley, R. J. Heine, RA DeFronzo, RL Hanson, RM Watanabe, SA Schafer, SA Schafer, SC Elbein, TM Frayling, TM Frayling, WC Hsueh, Y Hong   +49 more
core   +4 more sources

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Entwicklung eines Radiopharmakons zur Darstellung von Insulinomen im Tiermodell auf Basis des Inkretinhormons GLP-1(7-36)amid und seiner Analoga [PDF]

, 2003
Die non-invasive Lokalisationsdiagnostik von Insulinomen ist ein Problem, das bis heute nicht zufriedenstellend gelöst ist. In der vorliegenden Arbeit wurden Radiopharmaka zur szintigraphischen Darstellung von Insulinomen auf der Basis von GLP-1-Analoga ...
Behr, Thomas M. (Prof. Dr.), Fischer, Marc   +1 more
core   +1 more source

Comprehensively prognostic and immunological analyses of GLP-1 signaling-related genes in pan-cancer and validation in colorectal cancer

Frontiers in Pharmacology
Background: Glucagon-like peptide-1 (GLP-1) has crucial impact on glycemic control and weight loss physiologically. GLP-1 receptor agonists have been approved for treatment of diabetes and obesity.
Chaojun Zhu, Yihong Lai, Chengdong Liu, Lan Teng, Yuxin Zhu, Xinyu Lin, Xinyi Fu, Qiuhua Lai, Side Liu, Side Liu, Xiaohan Zhou, Yuxin Fang   +11 more
doaj   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. [PDF]

, 2014
OBJECTIVE: The colonic microbiota ferment dietary fibres, producing short chain fatty acids. Recent evidence suggests that the short chain fatty acid propionate may play an important role in appetite regulation.
Chambers, E.S., Viardot, A., Psichas, A., Morrison, D.J., Murphy, K.G., Zac-Varghese, S.E., MacDougall, K., Preston, T., Tedford, C., Finlayson, G.S., Blundell, J.E., Bell, J.D., Thomas, E.L., Mt-Isa, S., Ashby, D., Gibson, G.R., Kolida, S., Dhillo, W.S., Bloom, S.R., Morley, W., Clegg, S., Frost, G.S., Sagen E K Zac-Varghese, Chambers, E.S., Viardot, A., Psichas, A., Morrison, D.J., Murphy, K.G., Zac-Varghese, S.E., MacDougall, K., Preston, T., Tedford, C., Finlayson, G.S., Blundell, J.E., Bell, J.D., Thomas, E.L., Mt-Isa, S., Ashby, D., Gibson, G.R., Kolida, S., Dhillo, W.S., Bloom, S.R., Morley, W., Clegg, S., Frost, G.S., Sagen E K Zac-Varghese   +45 more
core   +4 more sources